Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase. clinical trial.

被引：1
|
作者：
Wang, Junsheng
Wu, Tao
Luo, Suxia
Li, Ning
Hong, Yonggui
Guo, Yanzhen
Cheng, Yufeng
Li, Baosheng
机构：
[1] Anyang Canc Hosp, Anyang, Peoples R China
[2] AnYang Tumor Hosp, Anyang, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[5] Shandong Univ, Qilu Hosp, Jinan, Peoples R China
[6] Shandong Canc Hosp, Jinan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.315
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
315
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial.
    Wang, Junsheng
    Wu, Tao
    Luo, Suxia
    Li, Ning
    Hong, Yonggui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Updated results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase. clinical trial.
    Li, Ning
    Wu, Tao
    Hong, Yong-Gui
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Wang, Junsheng
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 376 - 376
  • [3] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line treatment for patients with advanced ESCC: A multicenter, single-arm, open-label phase II clinical trial
    Wang, J.
    Wu, T.
    Hong, Y-G.
    Luo, S-X.
    Li, N.
    Guo, Y-Z.
    Cheng, Y-F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1058 - S1058
  • [4] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase II clinical trial.
    Wang Junsheng
    Luo Suxia
    Li Ning
    Wu Tao
    Hong Yonggui
    Guo Yanzhen
    Cheng Yufeng
    Li Baosheng
    Tan Bingxu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [5] Paclitaxel and cisplatin combined with anlotinib as first line regimen for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicentre open-label phase II clinical trial
    Wang, J-S.
    Wu, T.
    Hong, Y-G.
    Guo, Y-Z.
    Luo, S-X.
    Li, N.
    Cheng, Y-F.
    Li, B-S.
    ANNALS OF ONCOLOGY, 2020, 31 : S910 - S911
  • [6] Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Chang, Zhiwei
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Wang, Rui-Rui
    Jia, Yong-Xu
    Yan, Jie
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase. trial
    Wang, Junsheng
    Li, Ning
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Luo, Su-xia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Anlotinib in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase. trial.
    Wu, Xiaohua
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Chang, Zhiwei
    Wang, Rui-Rui
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 367 - 367
  • [10] Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase. clinical trial.
    Yang, Xiuli
    Meng, Xiangrui
    Hong, Yong-Gui
    Zhang, Zhiye
    Xia, Jin
    Wu, Tao
    Chen, Yunfang
    Shan, Zheng-Zheng
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 377 - 377
12345